ACTU (Actuate Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Actuate Therapeutics's net issuance of preferred for the three months ended in Mar. 2025 was $0.00 Mil. The number is 0, which means that Actuate Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Actuate Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Actuate Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Actuate Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Net Issuance of Preferred Stock Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

19.26

4.14

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Issuance of Preferred Stock	Get a 7-Day Free Trial					-	-	-	-	-

Actuate Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Actuate Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.